Research ArticleOriginal Research

A Lifestyle Intervention Study in Patients with Diabetes or Impaired Glucose Tolerance: Translation of a Research Intervention into Practice

Oksana A. Matvienko and James D. Hoehns
The Journal of the American Board of Family Medicine September 2009, 22 (5) 535-543; DOI: https://doi.org/10.3122/jabfm.2009.05.090012

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Flow of participants through the study.

  • Figure 2.
    Figure 2.

    Change in the percentage body weight during the course of the study for each participant (n = 28). *Data for change in weight between baseline and 12 months were not available for participants who did not complete the 12-month assessment (n = 3).

  • Figure 3.
    Figure 3.

    Correlation between the percentage of weight loss (baseline to 12 months) and hemoglobin A1c (n = 19) using Pearson correlation (r = 0.608; P = .006; n = 19).

Tables

  • Table 1.

    Baseline Characteristics of Participants (n = 31)

    CharacteristicN (%)Mean ± SD (Range)
    Age55.8 ± 8.9 (29–66)
    Sex
        Female19 (61)
        Male12 (39)
    Race
        White29 (94)
        African American1 (3)
        Asian American1 (3)
    Diagnosed with diabetes14 (45)
    Diagnosed with IGT14 (45)
    Classified as “high risk”3 (10)
    Self-reported history of smoking
        Never smoked15 (48.6)
        Smoked in the past14 (45.4)
        Current smoker2 (6)
    Family history of diabetes26 (84)

    • IGT, impaired glucose tolerance.

  • Table 2.

    The Effects of the Intervention on Anthropometric Measurements and Blood Pressure

    OutcomeBaseline (n = 28)6 Months (n = 28)P*12 Months (n = 25)P†
    Weight (kg)100.2 ± 21.1 (69.1–153.3)94.1 ± 20.2 (67.7–150.3)<.00194.1 ± 19.6 (66.0–148.5).001
    BMI (kg/m2)36.1 ± 6.7 (26.3–53.3)34.0 ± 6.8 (25.9–50.9)<.00134.0 ± 6.7 (25.5–51.9).001
    Waist circumference (cm)109.5 ± 16.0 (79.0–143.0)105.0 ± 16.8 (78.0–141.0)<.001104.2 ± 16.1 (75.1–137.7).002
    Hip circumference (cm)118.5± 14.8 (97.1–156.9)114.5 ± 14.1 (95.0–143.1)<.001114.6 ± 13.8 (95.5–145.3).001
    Waist-to-hip ratio0.93 ± 0.1 (0.7–1.2)0.92 ± 0.1 (0.8–1.1).1060.91 ± 0.1 (0.7–1.1).072
    Systolic blood pressure (mm Hg)130.0 ± 13.4 (104–176)123.9 ± 16.4 (96–197).064126.9 ± 15.8 (103–170).241
    Diastolic blood pressure (mm Hg)82.6 ± 9.6 (59–98)77.1 ± 10.8 (60–95).01178.5 ± 10.7 (64–102).024

    • Values shown as mean ± SD (range).

    • * Results of the paired samples t test, comparisons of 6-month and baseline values.

    • † Results of the paired samples t test, comparisons of 12-month and baseline values.

  • Table 3.

    Frequency of Medication Changes Related to Hypertension, Diabetes, or Hyperlipidemia*

    MedicationNew Drug StartDose of Existing Drug IncreasedDose of Existing Drug DecreasedDrug Discontinuation
    Antihypertensive0221
    Diabetes3205
    Antihyperlipidemic4126
    Total75412

    • * Medication changes pertaining to hypertension, diabetes, or hyperlipidemia occurred in 13 participants during the study period.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section